Comparison of restenosis rate with sirolimus-eluting stent in STEMI patients with and without diabetes at 6-month angiographic follow-up.

Abstract

OBJECTIVE:

Patients with diabetes mellitus (DM) are at high risk for restenosis after coronary stenting. However, whether drug-eluting stents are effective in diabetic patients presenting with ST-segment elevation myocardial infarction (STEMI) is uncertain. We report on a series of patients with or without DM followed up for 6 months after sirolimus-eluting stent implantation.

METHODS:

This cohort study enrolled 195 STEMI patients who underwent sirolimus-eluting stent implantation and accepted angiographic followup at 6 months.

RESULTS:

There were no significant differences between the two groups in baseline clinical characteristics and risk factors. The two groups were treated with similar stent lengths and diameters. The unadjusted in-stent restenosis was significantly higher in diabetic than in non-diabetic patients at 6 months (7.8 vs. 1.7, P < 0.05). Multivariate analysis showed that only diabetes and current smoking were independent predictors of restenosis (odds ratio 12.82 and 7.98, respectively, both P < 0.05).

CONCLUSION:

The present study demonstrated that diabetes increased restenosis after sirolimus-eluting stent placement in STEMI patients. This finding implicates that diabetes remains an important predictor for restenosis in the DES era.

• Authors: Shuangtao Ma, Dachun Yang, Xin Zhang, Bing Tang, De Li, Meiqin Sun, Yongjian Yang
• Journal: Acta cardiologica (Acta Cardiol) Vol. 66 Issue 5 Pg. 603-6 (Oct 2011) ISSN: 0001-5385 [Print] England
• PMID: 22032054 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Immunosuppressive Agents
• Sirolimus

Topics

• Aged
• Angioplasty, Balloon, Coronary
• Cohort Studies
• Coronary Angiography
• Coronary Artery Disease (diagnostic imaging, therapy)
• Coronary Restenosis (diagnostic imaging, etiology, therapy)
• Diabetes Complications (diagnostic imaging, therapy)
• Disease-Free Survival
• Drug-Eluting Stents
• Female
• Follow-Up Studies
• Humans
• Immunosuppressive Agents (administration & dosage)
• Male
• Middle Aged
• Multivariate Analysis
• Risk Factors
• Sirolimus (administration & dosage)
• Smoking (adverse effects)
• Treatment Outcome